Products for Research Use Only

Hydrochlorothiazid-d2

CAT: 0804-HY-B0252SSize: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0252SSize:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect[1][2][3].
CAS Number
1219798-89-6
Product Name Alternative
HCTZ-d2
UNSPSC
12352005
Target
Potassium Channel; TGF-beta/Smad
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Metabolic Disease; Cardiovascular Disease
Purity
98.52
Solubility
10 mM in DMSO|DMSO : 50mg/mL (ultrasonic)
Smiles
O=S1(C2=CC(S(N)(=O)=O)=C(Cl)C=C2NC([2H])([2H])N1)=O
Molecular Formula
C7H6D2ClN3O4S2
Molecular Weight
299.75
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Duarte, J.D. and R.M. Cooper-DeHoff, Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther, 2010. 8 (6) : p. 793-802.|[3]Magdy M Abdelquader, et al. Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination. AAPS PharmSciTech. 2018 Dec 17;20 (1) :3.|[4]Jinghong Luo, et al. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovasc Ther. 2017 Apr;35 (2) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported